218 related articles for article (PubMed ID: 32478632)
1. Tenapanor for the treatment of irritable bowel syndrome with constipation.
Sinagra E; Rossi F; Raimondo D; Conoscenti G; Anderloni A; Guarnotta V; Maida M
Expert Rev Clin Pharmacol; 2020 May; 13(5):473-479. PubMed ID: 32478632
[TBL] [Abstract][Full Text] [Related]
2. Tenapanor hydrochloride for the treatment of constipation-predominant irritable bowel syndrome.
Zielińska M; Wasilewski A; Fichna J
Expert Opin Investig Drugs; 2015; 24(8):1093-9. PubMed ID: 26065434
[TBL] [Abstract][Full Text] [Related]
3. Tenapanor for constipation-predominant irritable bowel syndrome.
Siddiqui S; Cash BD
Drugs Today (Barc); 2020 Mar; 56(3):203-210. PubMed ID: 32282867
[TBL] [Abstract][Full Text] [Related]
4. Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial.
Chey WD; Lembo AJ; Rosenbaum DP
Am J Gastroenterol; 2017 May; 112(5):763-774. PubMed ID: 28244495
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1).
Chey WD; Lembo AJ; Rosenbaum DP
Am J Gastroenterol; 2020 Feb; 115(2):281-293. PubMed ID: 31934897
[TBL] [Abstract][Full Text] [Related]
6. A pharmacokinetic evaluation of tenapanor for the treatment of irritable bowel syndrome with constipation: an update of the literature.
Currò D; Ianiro G; Gasbarrini A
Expert Opin Drug Metab Toxicol; 2023 Dec; 19(12):889-894. PubMed ID: 38108081
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2).
Chey WD; Lembo AJ; Yang Y; Rosenbaum DP
Am J Gastroenterol; 2021 Jun; 116(6):1294-1303. PubMed ID: 33337659
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety of tenapanor in patients with irritable bowel syndrome with constipation in the T3MPO-3 study.
Lembo AJ; Friedenberg KA; Fogel RP; Edelstein S; Zhao S; Yang Y; Rosenbaum DP; Chey WD
Neurogastroenterol Motil; 2023 Nov; 35(11):e14658. PubMed ID: 37668173
[TBL] [Abstract][Full Text] [Related]
9. Tenapanor (Ibsrela) for irritable bowel syndrome with constipation.
Med Lett Drugs Ther; 2022 Jun; 64(1652):91-94. PubMed ID: 35657365
[No Abstract] [Full Text] [Related]
10. Tenapanor: First Approval.
Markham A
Drugs; 2019 Nov; 79(17):1897-1903. PubMed ID: 31677150
[TBL] [Abstract][Full Text] [Related]
11. Plecanatide for the treatment of constipation-predominant irritable bowel syndrome.
Miner PB
Expert Rev Gastroenterol Hepatol; 2020 Feb; 14(2):71-84. PubMed ID: 31985305
[No Abstract] [Full Text] [Related]
12. New pharmacological treatment options for irritable bowel syndrome with constipation.
Nusrat S; Miner PB
Expert Opin Emerg Drugs; 2015; 20(4):625-36. PubMed ID: 26548544
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis.
Black CJ; Burr NE; Quigley EMM; Moayyedi P; Houghton LA; Ford AC
Gastroenterology; 2018 Dec; 155(6):1753-1763. PubMed ID: 30144426
[TBL] [Abstract][Full Text] [Related]
14. Tenapanor (Ibsrela) for the Treatment of Irritable Bowel Syndrome With Constipation.
Curtis S; Curtis M
Am Fam Physician; 2022 Jun; 105(6):656-658. PubMed ID: 35704831
[No Abstract] [Full Text] [Related]
15. A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers.
Johansson S; Rosenbaum DP; Knutsson M; Leonsson-Zachrisson M
Clin Exp Nephrol; 2017 Jun; 21(3):407-416. PubMed ID: 27368672
[TBL] [Abstract][Full Text] [Related]
16. Update on Pharmacotherapy for Irritable Bowel Syndrome.
Munjal A; Dedania B; Cash B
Curr Gastroenterol Rep; 2019 Apr; 21(6):25. PubMed ID: 31025114
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial.
Block GA; Rosenbaum DP; Yan A; Chertow GM
J Am Soc Nephrol; 2019 Apr; 30(4):641-652. PubMed ID: 30846557
[TBL] [Abstract][Full Text] [Related]
18. Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.
Jadallah KA; Kullab SM; Sanders DS
World J Gastroenterol; 2014 Jul; 20(27):8898-909. PubMed ID: 25083062
[TBL] [Abstract][Full Text] [Related]
19. NHE3 inhibitor tenapanor maintains intestinal barrier function, decreases visceral hypersensitivity, and attenuates TRPV1 signaling in colonic sensory neurons.
King AJ; Chang L; Li Q; Liu L; Zhu Y; Pasricha PJ; Wang J; Siegel M; Caldwell JS; Edelstein S; Rosenbaum DP; Kozuka K
Am J Physiol Gastrointest Liver Physiol; 2024 May; 326(5):G543-G554. PubMed ID: 38252683
[TBL] [Abstract][Full Text] [Related]
20. Abdominal Symptom Improvement During Clinical Trials of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation: A Post Hoc Analysis.
Lembo AJ; Chey WD; Harris LA; Frazier R; Brenner DM; Chang L; Lacy BE; Edelstein S; Yang Y; Zhao S; Rosenbaum DP
Am J Gastroenterol; 2024 May; 119(5):937-945. PubMed ID: 38294158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
